News UK budget includes £1bn biopharma investment package UK Chancellor John Healey's first Budget speech included a £1bn-plus industry investment package at sites in Manchester, Oxford, and Loughborough.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.